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Abstract
Background: In the cancer of the esophagus, with recent technologic advances, self-expanding metal stents
(SEMS) are at the forefront of the armamentarium for re-establishing luminal patency. Weighed against the
numerous advantages of stents are the import conditions and the cost. In light of this, we tested new low cost
prostheses having the basic needs and characteristics to aim a significant benefit to poor people having advanced
esophageal cancer, in a Brazilian regional public hospital.
Methods: This initial experience included fifteen patients (eleven men and four women, 55 ± 6.17 years old),
presenting esophageal cancer, located at the medium third of the thoracic esophagus, extending for 5.5-8 cm
long, not suitable for surgical procedure because they had been staged on fourth grade of the disease, two of
them having fistula communicating esophagus to respiratory tree. The stents were placed under endoscopic and
fluoroscopic guidance, after attempting an esophageal dilatation. An appropriate covered stent was then deployed,
twelve of 10 cm and three of 13 cm in length. A chest X-ray was done 2 h after the procedure and a barium
swallow was performed within 12 hours. Seven days and monthly until complete a six month follow-up after the
procedure the patients were questioned about presence of pain, regurgitation, heartburn, cough, and their
alimentary behavior.
Results: There were no severe complications and transient mild chest pain resolved until the seventh day after the
stent deployment. Chest X-ray demonstrated expansion of the stent in all patients. In 2 cases of fistula, a barium
swallow showed its complete sealing. The completion of the proposed follow-up was not achieved in three cases,
limited by the patient’s death until the third month, due to cancer progression. Recurrent dysphagia to paste food
accounted for by tumor overgrowth proximal or distal to the stent and stent migration were not observed in the series.
Conclusions: The new low cost endoprostheses is effective and forthcoming increased experience and prospective
trials including questionnaires to analyze quality of life will allow for more informed decisions tailoring to a
particular patient situation or to unexpected complications.
Background
In the cancer of the esophagus, for both palliation of
obstructive symptoms and continued oral intake, the
placement of an endoprostheses can greatly enhance the
quality of life of the patient. With recent technologic
advances, self-expanding metal stents (SEMS) are at the
forefront of the armamentarium for reestablishing lumi-
nal patency.
Progressive dysphagia, initially to solids, later to liquids
and secretions, is one of the most frequent debilitating
complaints. The prognosis is dismal: more than 60% of
patients are not operable at the time of diagnosis, and the
overall 5-year survival is lesser than 5% [1]. Palliation is
t h eo n l yr e a l i s t i ct h e r a p e u t i coption for these patients.
Available palliative treatment modalities include che-
motherapy, radiation therapy, esophageal bypass, esopha-
geal dilation, multipolar electrocoagulation, laser
treatment, injection of sclerosing agents, photodynamic
therapy, and esophageal endoprostheses.
Esophageal endoprostheses have been increasingly
used in this setting and currently comprise semi rigid
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Both types of endoprostheses provide rapid and lasting
relief of dysphagia.
However, plastic stents require general anesthesia for
placement and carry a high complication rate, with
stent-related mortality ranging from 4% to 13% [2].
With the ever decreasing diameters of delivery systems,
self-expanding metal mesh stents can be easily inserted
in an outpatient procedure using conscious sedation.
And, with advancement in user-friendly designs, there
has been continued improvement in the safety and ease
with which these devices can be inserted.
In past decade, several prospective randomized trials
demonstrated a higher effectiveness and much lower
complication (0% vs. 21%) and mortality (0% vs. 15.8%)
rate for SEMS vs. plastic stents, respectively [3,4]. SEMS
were also shown to be more cost-effective, considering
the shorter hospital stay and lower mortality [2]. Addi-
tional applications for SEMS, such as treatment of
bronchoesophageal fistulas, have emerged.
Earlier, uncovered (bare metal) designs allowed
ingrowths of tumor through wire mesh, causing the
stents to anchor in place. In contrast, covered versions
effectively prevent such tumor ingrowths but have a
higher rate of migration. Because the goal of SEMS is to
maintain luminal patency, there must be a favorable bal-
ance between migration rates and prevention of tumor
ingrowths. Current designs generally incorporate a cov-
ered midsection with uncovered flared ends that provide
an anchoring mechanism.
Data comparing the effectiveness, complication rates,
and costs for different stent types are limited. Currently,
the choice of particular SEMS depends primarily on the
physician’s experience and preference. Stent technology
and design continue to evolve with the goal of improv-
ing safety parameters [5].
In order to comprehensively assess the relative merits
of the different palliative treatments of malignant dys-
phagia, health economic aspects have to be incorpo-
rated. Weighed against the numerous advantages of
stents, particularly in the Brazilian public health net, are
the import conditions and the cost. In light of this, we
sought to employ immediately, as soon as approved
by ANVISA (Brazilian Official Office that certifies
health products) a prostheses (registration number
10159030069) that would enable, in the case of all those
providing services to patients with unresectable esopha-
geal cancer, prompt and accessible action in the treat-
ment of these severely ill patients, at a cost of less than
US$ 1,500, quite reasonable when compared with the
average cost of £ 4,900 in the palliative care of patients
with inoperable esophageal cancer by other methods [5],
contributing objectively to Brazilian public health.
This prospective study was proposed to introduce the
use of the new stent in a regional public hospital and to
verify its first clinical results.
Methods
Fifteen patients (eleven men and four women, 55 ± 6.17
years old), presenting esophageal cancer, located at the
medium third of the thoracic esophagus, extending for
5.5-8 cm long were admitted to the Cancer Hospital
(Barretos-São Paulo). The Ethical-Scientific Commission
of the Hospital approved the study.
They were not suitable for surgical procedure because
they had been staged on fourth grade of the disease, two
of them having fistula communicating esophagus to
respiratory tree. The complete demographic, clinical,
imaging (barium study, chest and abdomen’s contrast-
enhanced computed tomography), endoscopic and histo-
logical findings (squamous cancer) had been previously
recorded and the inclusion criteria was locally advanced
unresectable cancer, with the patients having ability to
swallow liquids only. Their body mass index average
achieved 18.16 ± 2.17 Kg/m
2 and serum albumin, 2.9 ±
0.51 g/100 mL.
The self-expandable stent for the esophagus is made
o fb r a i d e dS E 5 0 8n i t i n o l ,ab i n a r ya l l o ys u i t a b l ef o r
superelastic monofilament wires, composed of Ni
(55.8%), Ti (44.17%), O (0.02%), H (0.0001%) and C
(0.0039%), forming diamond shapes. It has nitinol wires
of 0.125 mm, 0.150 mm, 0.210 mm in diameter, respec-
tively, in grafts of 7, 10 and 13 cm in length.
The stent has an hourglass shape. Thus, its diameter
increases gradually, from the 20 mm of its tubular body,
up to 22 mm, along the 15 mm length of the outer
p a r t so fi t st a p e r e de n d sf i n i s h e dw i t hg o l dm a r k e r s .
The polyurethane coating (ASTM D-2240) has a hard-
ness of 75 (Shore), tensile strength of 7500 psi (ASTM
D-412) and 500% elongation (ASTM D-412). The stent
is coated but retains its conical ends of exposed wire
(Figure 1).
The self-expanding stent is inserted into a catheter
release mechanism and coaxial type sheath which has as
its components: handle, metal tubing, metal tubular
lock, hemostatic valve, sheath cover, an extractor to
release the prosthesis and a radiopaque silicon atrau-
matic tip. The release mechanism, with an internal dia-
meter allowing passage of a guide wire of up to 0.035
inch, is composed of two coaxial bodies, the insides of
which serves as internal housing for the stent and guide
wire passage. It is equipped with radiopaque markers on
its distal part for guidance on release and its proximal
part is embedded in the stem of stainless steel cable.
After obtaining informed consent, all patients were
submitted to the procedure and hospitalized for 24 h of
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kind of stent. The procedure was performed under local
anesthetic spray, using propofol for intravenous seda-
tion. The stents were placed under endoscopic and
fluoroscopic guidance. First, the guide wire was intro-
duced and an esophageal dilation was attempted (12
mm) under an image intensifier and then the location
and length of the stenosis was defined endoscopically.
The stricture was marked by contrast injection in its
extremities. An appropriate covered stent was then
deployed, twelve of 10 cm and three of 13 cm in length.
A chest X-ray was done 2 h after the procedure to
check the expansion of the stent and to look for any evi-
dence of surgical emphysema or pneumothorax. A bar-
ium swallow was performed within 12 hours.
Oral liquids were allowed after the chest X-ray and
t h eb a r i u ms w a l l o w ,a n dp a s t e sw e r ea u t h o r i z e da tt h e
outcome. All patients were advised to keep the head
end elevated during sleeping to prevent aspiration, to
chew food properly and to avoid consistent solid food.
Adjuvant therapy was not recommended due to the
poor clinical conditions of the patients.
Seven days and monthly until complete a six month
follow-up after the procedure the patients were ques-
tioned about presence of pain, regurgitation, heartburn,
cough, and their alimentary behavior.
Results
The mean ± SD propofol doses (mg/min per kg weight)
used was 0.14 ± 0.02. Stent placements were not asso-
ciated with any immediate or late technical complica-
tions. There were no severe complications, such as fistula
formation, sepsis, or death, due to esophageal stent place-
ment and transient mild chest pain, reported by all, was
controlled with paracethamol (750 mg twice a day)
resolved until the seventh day after the stent deployment.
Chest X-ray demonstrated expansion of the stent in all
patients and absence of esophageal perforation signs. In
2 cases of fistula, a barium swallow showed its complete
sealing (Figure 2). No severe chest pain, bleeding or
respiratory distress was reported. Regurgitation and
heartburn didn’t occur and cough diminished signifi-
cantly seven days after the sealing of the fistulas, enhan-
cing the quality of life of these terminal patients.
The completion of the proposed follow-up was not
achieved in three cases (stents of 13 cm in length; two
with esophageal fistula to respiratory tree), limited by
the patient’s death at 4-12 weeks after the procedure,
due to cancer progression, but until death they had pre-
served a free alimentary route without food impaction
or aspiration. Recurrent dysphagia to paste food
accounted for by tumor overgrowth proximal or distal
to the stent and stent migration were not observed in
the series until the sixth month.
Discussion
Palliation of malignant dysphagia is the mainstay of
therapy in patients with incurable esophageal cancer.
Figure 1 The new self-expandable stent for the esophagus.
Figure 2 Chest X-ray showing expansion of the stent, 2 h after
the procedure (left) and a barium swallow performed 12 h
after the procedure, documenting complete sealing of a fistula
(right).
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group of patients, mainly when cancer is located in the
thoracic esophagus, away from the cardia and the upper
esophageal sphincter (UES). Stents located through the
cardia have a high migration index and often cause
symptomatic reflux and those until 2 cm near the UES
determine continuous discomfort.
After undergoing esophageal stent placement, patients
need to modify their diet to prevent large boluses of
food from becoming impacted within the stent causing
immediate or late aspirationo ft h er e s i d u e sc o l l e c t e d
above. We didn’t have such complications, but the
patients were all instructed to sleep with the head of the
bed raised and to avoid consistent solid food, as a pro-
phylactic care.
Esophageal stent placement includes endoscopic
assessment, guide wire insertion, tumor dilation, and
stent deployment. Esophageal dilation is generally done
prior to stent insertion; precise requirements for dilation
depend on stent type.
Prior to stent placement, a complete endoscopic
examination should be performed to assess the proximal
and distal extent of the stricture. Dilation may be neces-
sary as a first step to allow a complete exam, but the
optimal degree of dilation prior to SEMS placement has
not been established. With the current small delivery
systems, it is generally recommended to dilate to at least
12 mm if possible, as we have done; under fluoroscopic
guidance, the most useful and safest method to perform
a stent placement [1,2], a guide wire can be safely
passed preceding dilation. The location of the tumor, at
t h em e d i u mt h i r do ft h et h o r a c i ce s o p h a g u s ,i na l lt h e
patients, and all those care measures mentioned above
certainly guaranteed the null rate of severe complica-
tions of this series, but greater casuistic maybe will pro-
voke inevitable unsuccessful cases.
When stenting mid-esophageal malignant strictures, as
in this series, it is wise to leave the final dilator in place
for 30-60 seconds to assess for respiratory compromise
due to tumor displacement. If such compromise occurs,
tracheal stenting to ensure airway patency should pre-
cede esophageal stent placement, what was not neces-
sary in any of our cases. A chest X-ray was performed
after stent placement to assess stent location and
exclude complications. When the stent is properly posi-
tioned, the esophageal stricture induces a “waist” at the
center of the stent immediately after deployment.
Procedure-related complications after stent placement,
which weren’t observed in this initial series, occur in 5%
to 10% of patients and mainly consist of perforation,
aspiration pneumonia, fever, hemorrhage, and severe
pain. Minor complications, which are reported by 10%
to 20% of patients, include mild retrosternal pain, as our
patients reported, and GE reflux symptoms. Delayed
complications and recurrent dysphagia to paste food fol-
lowing stent placement are important problems and
have been reported to occur in 30% to 40% of patients.
Delayed complications include hemorrhage, fistula for-
mation, stent migration, tissue ingrowths or overgrowth,
and food-bolus obstruction [6]. Possibly a great part of
these problems could be avoided reserving the stent to
mid esophagus tumors, not completely obstructive, as in
this series, avoiding endoprostheses and performing only
a gastrostomy in extremely severe grade of the disease.
The decreasing diameters of delivery systems make
perforation a rare occurrence, generally related to pre-
stent dilation. Chest pain seems to be related to the
expansible force of the stent, and generally resolves
within some days, as we observed. Most patients with
chest pain may be managed adequately with routine
analgesics, as we did.
A retrospective study compared two different types of
SEMS (uncovered and partially covered) for palliative
treatment of 152 patients (uncovered 54 and partially
covered 98) with inoperable malignant stenosis of the
esophagus and cardia [7]. Overall, 88% of patients with
partially covered stents and 54% with uncovered stents
were free of symptoms during follow-up (P < 0.0001).
Although the rates of stent migration were lower in the
uncovered stents group (0 vs. 10%, P = 0.03), tumor or
granulation tissue ingrowths (100 vs. 53%, P < 0.0001)
and restenosis causing recurrent dysphagia (37 vs. 8%, P
< 0.0001) were significantly higher in the uncovered
stents group.
It has now convincingly been shown that fully or par-
tially covered metal stents, our stent choice, give better
long-term palliation of malignant dysphagia than uncov-
ered stents. The technical success rate for placement of
partially or fully covered metal stents is close to 100%.
Almost all patients experience rapid improvement of
dysphagia within a few days [8], as in our initial series.
T h ee n d o s c o p i cp l a c e m e n to fc o v e r e dS E M Si st h e
treatment of choice for malignant esophageal fistulas.
The quality of the evidence for malignant fistula closure
with SEMS is moderate and the strength of the recom-
mendation is strong (given the paucity of alternatives).
When placing stents for this indication, it is imperative
to assess for airway compromise during dilation. If
respiratory distress occurs, tracheal stenting should be
performed prior to placement of the esophageal stent.
Fortunately we didn’t have this problem and the com-
plete closure of the fistula was showed in the barium
swallow performed 12 h after the procedure. As a con-
sequence, the patients had a grateful relief of the cough.
In three cases, the duration of follow-up was limited
to just 4-12 weeks by occurrence of the patient’sd e a t h
due to cancer progression. This fact correlates with the
advanced disease stage that these patients had prior to
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them showing an esophageal fistula to respiratory tree.
It is likely that esophageal stent placement would be
even more beneficial if done earlier in the disease
course.
Our first experience reveals that the majority of stents
certainly could be placed on an outpatient basis. The
patient should be observed for 2 hours after the proce-
dure, and if clinically stable and well receiving liquids
via oral route, could be discharged to home with dietary
instructions.
Conclusion
The new low cost endoprostheses is effective and forth-
coming increased experience and prospective trials
including questionnaires to analyze quality of life will
allow for more informed decisions tailoring to a particu-
lar patient situation or to unexpected complications.
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